Now based in Copenhagen, SB3000 ApS will have key operations in both the UK and Denmark.
Our science hub at DTU:
Swedish Biomimetics 3000 ApS
2800 Kongens Lyngby
Over the last several years, SB3000 has developed continuous manufacturing technology based on solid liquid-phase chemistry, including the development of a superior mixing technology using ultrasound to create a robust platform technology. This disruptive technology has already been proven in a proof of concept model.
Our precision engineering hub in Hethel:
Swedish Biomimetics 3000 Ltd,
Hethel Innovation Centre, Chapman Way,
Hethel, Norfolk, NR14 8FB
Swedish Biomimetics 3000 is at the forefront of creating a platform technology that will advance not only therapeutic peptide production but also any form of chemistry or process based on a solid-liquid phase interaction including chromatography.
We believe that the µLOT® process will speed up
development, reduce cost and enable the synthesis of drugs currently not economically or technically possible to produce. At present the process is applicable to 80% of the market. We are developing the technology to cover the remaining market by including novel peptide designs such as lipid- and antibody-conjugations.
JENS BUKRINSKY, Chief R&D Officer, SB3000®
ex. Pfizer, Wyeth, Rhone Poulenc, Orexo, ZEL Advisory Group
ex. ABG Sundal Collier, Directorships at misc. Biotech Boards
Chief R&D Officer
ex. Novo Nordisk, Novozymes
Director of Business Operations
ex. Novo Nordisk
Director of Technical Operations
formerly Active Technologies, Lotus Engineering & Stewart GP F1 team
formerly Lotus Engineering & AIC Labs
formerly Ferring, Astra Zeneca
BOARD & ADVISORS
Chairman & CEO SB3000
ApS, ex Pfizer, Wyeth, Rhone Poulenc, Orexo, ZEL Advisory Group
ex PWC Pharma & Life Science Lead
Wistrand Advokatbyra, Bird & Bird
Dr. Alain Scarso
ex UCB, Lonza, PolyPeptide
Prof Trevor Jones CBE
Hon FBPhS, Chair, Dir. Several global healthcare companies, ex-Head of R&D Wellcome
Experienced senior leader and board member in Pharma. Former EVP Ferring Pharmaceuticals.
Swedish based Swedish Biomimetics 3000 AB is a majority shareholder in SB3000 ApS, led by Lars Uno Larsson, a serial entrepreneur.
SB3000 AB is a pioneer in the field of biomimetics which is to find, develop and launch technologies inspired by nature and to apply them to today’s enviromental and climate change challenges .
SB3000 AB is also a majority investor in Swedish Biomimetics 3000 µMist Technologies Ltd, a disruptive innovative enviromental friendlier spray technology inspired by the Bombardier beetle. The µMist technology is set to disrupt a $200 billion spray market across a number of different industries.